These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20709650)

  • 1. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
    Jin K; Shen Y; He K; Xu Z; Li G; Teng L
    Clin Transl Oncol; 2010 Aug; 12(8):526-32. PubMed ID: 20709650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
    Lockhart AC; Rothenberg ML; Dupont J; Cooper W; Chevalier P; Sternas L; Buzenet G; Koehler E; Sosman JA; Schwartz LH; Gultekin DH; Koutcher JA; Donnelly EF; Andal R; Dancy I; Spriggs DR; Tew WP
    J Clin Oncol; 2010 Jan; 28(2):207-14. PubMed ID: 19949018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical applications of VEGF-trap (aflibercept) in cancer treatment.
    Teng LS; Jin KT; He KF; Zhang J; Wang HH; Cao J
    J Chin Med Assoc; 2010 Sep; 73(9):449-56. PubMed ID: 20875616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
    Wang-Gillam A; Tew WP; Rothenberg ML; Dupont J; Cooper W; Sternas L; Buzenet G; Sosman JA; Spriggs DR; Lockhart AC
    Invest New Drugs; 2012 Oct; 30(5):1958-61. PubMed ID: 22002018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
    Twardowski P; Stadler WM; Frankel P; Lara PN; Ruel C; Chatta G; Heath E; Quinn DI; Gandara DR
    Urology; 2010 Oct; 76(4):923-6. PubMed ID: 20646741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept: A Review in Metastatic Colorectal Cancer.
    Syed YY; McKeage K
    Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.
    Sharma T; Dhingra R; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
    Mini Rev Med Chem; 2013 Apr; 13(4):530-40. PubMed ID: 23317499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
    MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
    Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.
    Tew WP; Gordon M; Murren J; Dupont J; Pezzulli S; Aghajanian C; Sabbatini P; Mendelson D; Schwartz L; Gettinger S; Psyrri A; Cedarbaum JM; Spriggs DR
    Clin Cancer Res; 2010 Jan; 16(1):358-66. PubMed ID: 20028764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
    Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
    Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
    Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
    Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept (VEGF-TRAP): the next anti-VEGF drug.
    Stewart MW
    Inflamm Allergy Drug Targets; 2011 Dec; 10(6):497-508. PubMed ID: 21999177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors.
    Chu QS
    Expert Opin Biol Ther; 2009 Feb; 9(2):263-71. PubMed ID: 19236257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Systemic safety following intravitreal injections of anti-VEGF].
    Baillif S; Levy B; Girmens JF; Dumas S; Tadayoni R
    J Fr Ophtalmol; 2018 Mar; 41(3):271-276. PubMed ID: 29567019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
    van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
    J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
    [No Abstract]   [Full Text] [Related]  

  • 20. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
    Izzedine H
    Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.